Sorrento Therapeutics Statistics
Total Valuation
Sorrento Therapeutics has a market cap or net worth of 271,856. The enterprise value is 134.39 million.
| Market Cap | 271,856 |
| Enterprise Value | 134.39M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Sorrento Therapeutics has 543.71 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 543.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.50% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.04% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.25 |
| EV / Sales | 2.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.55 |
Financial Position
The company has a current ratio of 0.40
| Current Ratio | 0.40 |
| Quick Ratio | 0.34 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.85 |
| Interest Coverage | -52.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -40.81% |
| Return on Capital (ROIC) | -126.97% |
| Revenue Per Employee | 67,724 |
| Profits Per Employee | -577,448 |
| Employee Count | 949 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 14.61 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +681.65% in the last 52 weeks. The beta is 1.68, so Sorrento Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.68 |
| 52-Week Price Change | +681.65% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 361,932 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 11.56 |
Income Statement
In the last 12 months, Sorrento Therapeutics had revenue of 64.27 million and -548.00 million in losses. Loss per share was -1.08.
| Revenue | 64.27M |
| Gross Profit | -157.47M |
| Operating Income | -355.52M |
| Pretax Income | -571.49M |
| Net Income | -548.00M |
| EBITDA | -341.59M |
| EBIT | -355.52M |
| Loss Per Share | -1.08 |
Balance Sheet
The company has 80.64 million in cash and 207.60 million in debt, giving a net cash position of -126.97 million or -0.23 per share.
| Cash & Cash Equivalents | 80.64M |
| Total Debt | 207.60M |
| Net Cash | -126.97M |
| Net Cash Per Share | -0.23 |
| Equity (Book Value) | -197.96M |
| Book Value Per Share | -0.38 |
| Working Capital | -195.76M |
Cash Flow
In the last 12 months, operating cash flow was -234.63 million and capital expenditures -8.59 million, giving a free cash flow of -243.21 million.
| Operating Cash Flow | -234.63M |
| Capital Expenditures | -8.59M |
| Free Cash Flow | -243.21M |
| FCF Per Share | -0.45 |
Margins
| Gross Margin | -245.01% |
| Operating Margin | -553.17% |
| Pretax Margin | -889.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Sorrento Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50.62% |
| Shareholder Yield | -50.62% |
| Earnings Yield | -201,576.57% |
| FCF Yield | -89,463.54% |
Stock Splits
The last stock split was on August 1, 2013. It was a reverse split with a ratio of 0.04.
| Last Split Date | Aug 1, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
Sorrento Therapeutics has an Altman Z-Score of -9.2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.2 |
| Piotroski F-Score | n/a |